Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RGS12 | O14924 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31759018 | 1.00 | LMNA (0.43) | LMNAALDH1A1KMT2AMAPTHDAC1 | |
| SCHEMBL9906805 | 0.94 | LMNA (0.43) | LMNAALDH1A1KMT2AMAPTHDAC1 | |
| SCHEMBL16351468 | 0.84 | LMNA (0.50) | LMNAALDH1A1KMT2AMAPTHDAC1 | |
| SCHEMBL23133303 | 0.78 | ALDH1A1 (0.36) | LMNAALDH1A1KMT2AMAPTHDAC1 | |
| SCHEMBL10326593 | 0.76 | EHMT2 (0.55) | LMNAALDH1A1KMT2AMAPTHDAC1 | |
| SCHEMBL906678 | 0.76 | ALDH1A1 (0.55) | LMNAALDH1A1KMT2AMAPTHDAC1 | |
| SCHEMBL2025649 | 0.76 | ALDH1A1 (0.48) | LMNAALDH1A1KMT2AMAPTHDAC1 | |
| SCHEMBL12575473 | 0.76 | ALDH1A1 (0.55) | LMNAALDH1A1KMT2AMAPTHDAC1 | |
| SCHEMBL12575508 | 0.76 | ALDH1A1 (0.40) | LMNAALDH1A1KMT2AMAPTHDAC1 | |
| SCHEMBL11821480 | 0.75 | EHMT2 (0.57) | LMNAALDH1A1KMT2AMAPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115300-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2026-04-30 | — | — | US | disclosed |
| US-20260034226-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2026-02-05 | — | — | US | disclosed |
| US-20250295743-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2025-09-25 | — | — | US | disclosed |
| EP-4385520-A2 | GLYCOTARGETING THERAPEUTICS | Ecole Polytechnique Fédérale de Lausanne (CH) | 2024-06-19 | — | — | EP | disclosed |
| US-11801305-B2 | Glycotargeting therapeutics | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2023-10-31 | — | — | US | disclosed |
| US-11793882-B2 | Glycotargeting therapeutics | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11666638-B2 | Glycotargeting therapeutics | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2023-06-06 | — | — | US | disclosed |
| US-11654188-B2 | Glycotargeting therapeutics | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2023-05-23 | — | — | US | disclosed |
| US-20230119325-A1 | GLYCOTARGETING THERAPEUTICS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2023-04-20 | — | — | US | disclosed |
| US-20230115331-A1 | GLYCOTARGETING THERAPEUTICS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2023-04-13 | — | — | US | disclosed |
| US-20180271986-A1 | GLYCOTARGETING THERAPEUTICS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2018-09-27 | — | — | US | disclosed |
| EP-3349784-A1 | GLYCOTARGETING THERAPEUTICS | Ecole Polytechnique Fédérale de Lausanne (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-20170296636-A9 | GLYCOTARGETING THERAPEUTICS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2017-10-19 | — | — | US | disclosed |
| WO-2017046652-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2017-03-23 | — | — | WO | disclosed |
| CN-106456743-A | Glycotargeting therapeutics | 洛桑聚合联合学院 | 2017-02-22 | — | — | CN | disclosed |
| US-20170007708-A1 | GLYCOTARGETING THERAPEUTICS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2017-01-12 | — | — | US | disclosed |
| EP-3107563-A2 | GLYCOTARGETING THERAPEUTICS | Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO (CH) | 2016-12-28 | — | — | EP | disclosed |
| US-20160243248-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FED DE LAUSANNE (EPFL) (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20160015821-A1 | GLYCOTARGETING THERAPEUTICS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-01-21 | — | — | US | disclosed |
| WO-2015140648-A2 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECNIQUE FEDERALE DE LAUSANNE (EPFL) EPFL-TTO (CH) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11801305-B2 | Glycotargeting therapeutics | LGALS3BP, LGALS1, CD47 | LMNA 4132/4885ALDH1A1 1840/4885KMT2A 3102/4885 |
| US-20250295743-A1 | GLYCOTARGETING THERAPEUTICS | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885ALDH1A1 2577/4885KMT2A 3020/4885 |
| US-20160243248-A1 | GLYCOTARGETING THERAPEUTICS | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885ALDH1A1 2577/4885KMT2A 3020/4885 |
| US-11793882-B2 | Glycotargeting therapeutics | CD74, LGALS1, LY96 | LMNA 4673/4885ALDH1A1 1130/4885KMT2A 2614/4885 |
| US-20260034226-A1 | GLYCOTARGETING THERAPEUTICS | LGALS1, ST6GAL1, LGALS2 | LMNA 4291/4885ALDH1A1 460/4885KMT2A 3587/4885 |
| US-20170007708-A1 | GLYCOTARGETING THERAPEUTICS | CD74, LGALS1, LY96 | LMNA 4673/4885ALDH1A1 1130/4885KMT2A 2614/4885 |
| US-11654188-B2 | Glycotargeting therapeutics | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885ALDH1A1 2577/4885KMT2A 3020/4885 |
| US-11666638-B2 | Glycotargeting therapeutics | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885ALDH1A1 2577/4885KMT2A 3020/4885 |
| US-20230119325-A1 | GLYCOTARGETING THERAPEUTICS | LGALS3BP, LGALS1, CD47 | LMNA 4132/4885ALDH1A1 1840/4885KMT2A 3102/4885 |
| US-20260115300-A1 | GLYCOTARGETING THERAPEUTICS | CD74, HLA-DRB1, CD69 | LMNA 4625/4885ALDH1A1 555/4885KMT2A 3760/4885 |
| US-20230115331-A1 | GLYCOTARGETING THERAPEUTICS | CD74, LGALS1, LY96 | LMNA 4673/4885ALDH1A1 1130/4885KMT2A 2614/4885 |
| US-20180271986-A1 | GLYCOTARGETING THERAPEUTICS | LGALS3BP, LGALS1, CD47 | LMNA 4132/4885ALDH1A1 1840/4885KMT2A 3102/4885 |
| US-20160015821-A1 | GLYCOTARGETING THERAPEUTICS | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885ALDH1A1 2577/4885KMT2A 3020/4885 |
| US-20170296636-A9 | GLYCOTARGETING THERAPEUTICS | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885ALDH1A1 2577/4885KMT2A 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.